Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
Saved in:
| Title: | Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes. |
|---|---|
| Authors: | Hasanali ZS; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, Pennsylvania., Epner EM; Department of Hematology/Oncology, New Mexico VA Health Care System, Albuquerque, New Mexico., Feith DJ; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, Virginia., Loughran TP Jr; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, Virginia., Sample CE; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, Pennsylvania. csample@hmc.psu.edu. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 2784-92. Date of Electronic Publication: 2014 Oct 15. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1538-8514 |
|---|---|
| DOI: | 10.1158/1535-7163.MCT-14-0593 |
